HDACi 藥物根治 愛滋病 希望 !!! (Merck & Co published on Nature)

默克在Nature上发表文章证实可根除体内隐藏的HIV病毒 作者：jewell来源：生物谷2012-7-26 10:22:46 00 7月25日，默克公司（Merck & Co）宣布，7月26日自然（Nature）科学杂志将发表其研究成果，证实使用药物可能清除接受抗艾疗法患者体内隐藏的HIV病毒。来自默克研究实验室（Merck Research Laboratories）的科研人员联合分别来自北卡罗来纳大学（UNC）教堂山分校、哈弗大学公共卫生学院、美国国家癌症研究所及加州大学圣地牙哥分校的研究人员于去年发起一项研究，以寻找清除体内HIV持续感染的新途径。“我们相信，破坏和清除病毒蓄积是找到治愈HIV/AIDS疗法艰巨挑战中的关键性第一步，”默克研究实验室副总裁Daria Hazuda博士如是说。默克表示，这是第一个发表的在转化临床研究中表明组蛋白去乙酰基酶抑制物可作用于潜伏的休眠病毒的研究成果。该研究结果首先于今年3月在西雅图举行的逆转录病毒预计会感染会议（Conference on Retroviruses and Opportunistic Infections）上公布，并在最近于华盛顿举行的国际艾滋病会议（International AIDS Conference）上做相关报告。（生物谷Bioon.com）

Merck, Collaborators Publish Study Showing Potential for Eradication of Persistent HIV Virus in the Body July 25, 2012 05:03 PM Eastern Daylight Time

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the publication of a study in the July 26 issue of the leading scientific journal Nature that provided early evidence for the use of a drug to dislodge reservoirs of hidden virus in patients receiving treatment for HIV, the virus that causes AIDS. “We are excited about this pioneering research and remain hopeful for its potential.”Scientists from Merck Research Laboratories collaborated with researchers from the University of North Carolina (UNC) at Chapel Hill, the Harvard School of Public Health, National Cancer Institute, and the University of California at San Diego in the study in a collaboration initiated last year to identify new ways to purge persistent infection of HIV from the body. "We believe that the disruption and clearance of these virus reservoirs is a critical first step to the daunting challenge of finding a cure for HIV/AIDS," said Daria Hazuda, Ph.D., vice president, Merck Research Laboratories. "We are excited about this pioneering research and remain hopeful for its potential."This is the first published study to show the potential for histone deacetylase inhibitors to attack latency within dormant virus pools in a translational clinical study. This research was first presented in March at the Conference on Retroviruses and Opportunistic Infections in Seattle and more recently at the International AIDS Conference in Washington DC.“This work provides compelling evidence to support a strategy to directly attack and eradicate latent HIV infection," said David Margolis, MD, professor of medicine, microbiology and immunology, and epidemiology at UNC at Chapel Hill, who led the study.The research conducted is part of a UNC-led consortium, the Collaboratory of AIDS Researchers for Eradication (CARE), funded by the National Institute of Allergy and Infectious Diseases. Funding for this research was provided by Merck, the National Institutes of Health, and the James B. Pendleton Charitable Trust.

Merck's history in HIV research and access Merck has been engaged in the fight against HIV/AIDS for more than two decades. In 1988, Merck researchers were the first to demonstrate that inhibiting the protease enzyme would prevent replication of HIV; the following year, Merck scientists published the first crystal structure for HIV protease. Years later, Merck scientists were the first to demonstrate inhibition of HIV integrase in vitro and in vivo. Currently Merck scientists are actively pursuing HIV research against at least five distinct targets and have several HIV compounds in development. Since our first HIV medicines became available, Merck has worked to expand access to these medicines, including through partnerships with others.